Published in Genes Dev on June 02, 2016
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell (2017) 1.39
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene (2016) 0.77
KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression. Neoplasia (2016) 0.76
Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther (2016) 0.75
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. Oncogene (2016) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Chromatin modifications and their function. Cell (2007) 55.98
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell (2006) 7.08
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J (1998) 5.21
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature (2006) 4.74
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res (2010) 3.74
Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol (2012) 3.40
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev (2006) 3.24
A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell (2010) 2.77
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet (2015) 2.34
Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov (2013) 2.16
Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity (1995) 2.12
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.69
KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res (2013) 1.65
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A (2012) 1.60
Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One (2011) 1.48
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun (2013) 1.37
Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood (2002) 1.30
The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev (2012) 1.20
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res (2014) 1.17
In focus: MLL-rearranged leukemia. Leukemia (2013) 1.14
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer (2015) 1.12
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development. Mol Cell Biol (2014) 1.07
The testis-enriched histone demethylase, KDM4D, regulates methylation of histone H3 lysine 9 during spermatogenesis in the mouse but is dispensable for fertility. Biol Reprod (2011) 1.04
A role for DOT1L in MLL-rearranged leukemias. Epigenomics (2011) 1.02
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol (2015) 0.93
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives. J Med Chem (2016) 0.89
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci U S A (2014) 0.87
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell (2016) 0.87
An interactive environment for agile analysis and visualization of ChIP-sequencing data. Nat Struct Mol Biol (2016) 0.86
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. J Med Chem (2016) 0.86
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. J Med Chem (2016) 0.82
Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. EMBO J (2016) 0.81
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell (2015) 0.81
CD123 and its potential clinical application in leukemias. Life Sci (2014) 0.80
Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia. J Leukoc Biol (2014) 0.79
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med (2017) 1.08
Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev (2016) 1.08
DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia (2016) 0.83
Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. EMBO J (2016) 0.81
Jarid2 binds mono-ubiquitylated H2A lysine 119 to mediate crosstalk between Polycomb complexes PRC1 and PRC2. Nat Commun (2016) 0.78
Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression. Nucleic Acids Res (2016) 0.78
ZFP57 maintains the parent-of-origin-specific expression of the imprinted genes and differentially affects non-imprinted targets in mouse embryonic stem cells. Nucleic Acids Res (2016) 0.75
Maternal expression of the histone demethylase Kdm4a is crucial for pre-implantation development. Development (2017) 0.75